A federal district judge in Washington, D.C., has paused Boehringer Ingelheim’s (BI) 340B contract pharmacy lawsuit while the federal government decides whether to appeal the same judge’s Nov. 5 joint ruling in Novartis and United Therapeutics’ (UT) contract pharmacy suits.
U.S. District Judge Dabney Fredrich on Dec. 9 granted the government and BI’s joint motion for a stay. BI is challenging the government’s Oct. 4 determination that the company’s restrictions on 340B pricing when hospitals use contract pharmacies are illegal. Novartis and UT likewise sued the government after both got similar 340B program violation notices about their contract pharmacy policies.
A federal district judge in Washington, D.C., has paused Boehringer Ingelheim’s (BI) 340B contract pharmacy lawsuit while the federal government decides whether to appeal the same judge’s Nov. 5 joint ruling in Novartis and United Therapeutics’ (UT) contract pharmacy suits.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
